Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease Gastroenterology : 2017.
Herfarth HH, Jackson S, Schliebe B, Martin C, Ivanova A, Anton K, Sandler RS, Long MD, Isaacs KL, Osterman MT, Sands BE, Higgins PD, Lewis JD: Investigator initiated IBD trials in the US: Facts, obstacles and answers Inflammatory Bowel Diseases 23 (1): 14-22,2017.
Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive versus reactive therapeutic drug monitoring of infliximab in inflammatory bowel disease Gastroenterology : 2017.
Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive compared to reactive therapeutic drug monitoring of infliximab is associated with less IBD-related surgery and hospitalization Gastroenterology : 2017.
Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology : 2017.
Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab Clinical Gastroenterology and Hepatology : 2017.
Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies Gastroenterology : 2017.
Chachu KA, Osterman MT: How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD Inflammatory Bowel Diseases 22 (5): 1262-74,2016.
Osterman MT, Lichtenstein GR: Chapter 116: Ulcerative Colitis Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition : 2023-61,2016.
Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Predictors and Clinical Impact of Indeterminate QuantiFERON-TB Gold Testing in Inflammatory Bowel Disease Pharmacoepidemiology and Drug Safety : 2016.
View all publications